Novartis AG (NVS)
NYSE: NVS · Real-Time Price · USD
166.11
+3.01 (1.85%)
Feb 17, 2026, 11:15 AM EST - Market open
Novartis AG Employees
Novartis AG had 75,267 employees as of December 31, 2025. The number of employees decreased by 616 or -0.81% compared to the previous year.
Employees
75,267
Change (1Y)
-616
Growth (1Y)
-0.81%
Revenue / Employee
$752,973
Profits / Employee
$185,792
Market Cap
313.57B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,267 | -616 | -0.81% |
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | 105,794 | 1,880 | 1.81% |
| Dec 31, 2019 | 103,914 | -21,247 | -16.98% |
| Dec 31, 2018 | 125,161 | 3,564 | 2.93% |
| Dec 31, 2017 | 121,597 | 3,204 | 2.71% |
| Dec 31, 2016 | 118,393 | -307 | -0.26% |
| Dec 31, 2015 | 118,700 | -14,713 | -11.03% |
| Dec 31, 2014 | 133,413 | -2,283 | -1.68% |
| Dec 31, 2013 | 135,696 | 7,972 | 6.24% |
| Dec 31, 2012 | 127,724 | 4,038 | 3.26% |
| Dec 31, 2011 | 123,686 | 4,268 | 3.57% |
| Dec 31, 2010 | 119,418 | 19,584 | 19.62% |
| Dec 31, 2009 | 99,834 | 3,117 | 3.22% |
| Dec 31, 2008 | 96,717 | -1,483 | -1.51% |
| Dec 31, 2007 | 98,200 | -2,535 | -2.52% |
| Dec 31, 2006 | 100,735 | 9,735 | 10.70% |
| Dec 31, 2005 | 91,000 | 9,600 | 11.79% |
| Dec 31, 2004 | 81,400 | 2,859 | 3.64% |
| Dec 31, 2003 | 78,541 | 5,664 | 7.77% |
| Dec 31, 2002 | 72,877 | 2,557 | 3.64% |
| Dec 31, 2001 | 70,320 | 1,252 | 1.81% |
| Dec 31, 2000 | 69,068 | -13,391 | -16.24% |
| Dec 31, 1999 | 82,459 | -3,376 | -3.93% |
| Dec 31, 1998 | 85,835 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 92,900 |
| Sanofi | 82,878 |
| Pfizer | 81,000 |
| Merck & Co. | 75,000 |
| Novo Nordisk | 69,505 |
| GSK plc | 68,629 |
| AbbVie | 55,000 |
NVS News
- 4 days ago - Novartis Says Vanrafia Drug Slows Kidney Function Decline - WSJ
- 4 days ago - Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy - GlobeNewsWire
- 8 days ago - Oakmark International Strategy Q4 2025 New Investments And Divestments - Seeking Alpha
- 12 days ago - Novartis: Value Price, Growth Pipeline - Seeking Alpha
- 12 days ago - Novartis AG (NVS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Benzinga
- 13 days ago - Novartis Sales Rise Despite Generic Drug Competition in U.S. - WSJ
- 13 days ago - Novartis expects low single-digit decline in 2026 operating profit - Reuters